BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33422900)

  • 1. Clinicopathologic Characteristics and Prognosis of Invasive Papillary Carcinoma of the Breast.
    Huang K; Appiah L; Mishra A; Bagaria SP; Gabriel ME; Misra S
    J Surg Res; 2021 May; 261():105-112. PubMed ID: 33422900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of clinicopathologic characteristics and molecular subtypes of invasive papillary carcinoma of the breast and invasive ductal carcinoma: results from SEER database.
    Chen S; Wang J; Yang L; Ji M; Chen S
    J BUON; 2021; 26(5):1991-2002. PubMed ID: 34761609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic characteristics and molecular subtypes of invasive papillary carcinoma of the breast: a large case study.
    Liu ZY; Liu N; Wang YH; Yang CC; Zhang J; Lv SH; Niu Y
    J Cancer Res Clin Oncol; 2013 Jan; 139(1):77-84. PubMed ID: 22932921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in Prognostic Factors and Failure Patterns Between Invasive Micropapillary Carcinoma and Carcinoma With Micropapillary Component Versus Invasive Ductal Carcinoma of the Breast: Retrospective Multicenter Case-Control Study (KROG 13-06).
    Yu JI; Choi DH; Huh SJ; Cho EY; Kim K; Chie EK; Ha SW; Park IA; Ahn SJ; Lee JS; Shin KH; Kwon Y; Kim YB; Suh CO; Koo JS; Kim JH; Jeong BG; Kim IA; Lee JH; Park W
    Clin Breast Cancer; 2015 Oct; 15(5):353-61.e1-2. PubMed ID: 25776197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive micropapillary carcinoma of the breast had poor clinical characteristics but showed no difference in prognosis compared with invasive ductal carcinoma.
    Li G; Yang S; Yao J; Wang Z; Yao G; Liu M; Ye C
    World J Surg Oncol; 2016 Aug; 14(1):207. PubMed ID: 27492008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive micropapillary carcinoma of the breast has a better long-term survival than invasive ductal carcinoma of the breast in spite of its aggressive clinical presentations: a comparison based on large population database and case-control analysis.
    Chen H; Wu K; Wang M; Wang F; Zhang M; Zhang P
    Cancer Med; 2017 Dec; 6(12):2775-2786. PubMed ID: 29072365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
    Zhao H
    Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in prognostic factors and patterns of failure between invasive micropapillary carcinoma and invasive ductal carcinoma of the breast: matched case-control study.
    Yu JI; Choi DH; Park W; Huh SJ; Cho EY; Lim YH; Ahn JS; Yang JH; Nam SJ
    Breast; 2010 Jun; 19(3):231-7. PubMed ID: 20304650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast.
    Chen AC; Paulino AC; Schwartz MR; Rodriguez AA; Bass BL; Chang JC; Teh BS
    Br J Cancer; 2014 Jul; 111(3):619-22. PubMed ID: 24921921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
    Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
    Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracystic papillary carcinoma: a review of 917 cases.
    Grabowski J; Salzstein SL; Sadler GR; Blair S
    Cancer; 2008 Sep; 113(5):916-20. PubMed ID: 18661510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis.
    Wu Y; Zhang N; Yang Q
    BMC Cancer; 2017 Dec; 17(1):839. PubMed ID: 29228910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracystic papillary carcinoma: clinical presentation, patterns of practice, and oncological outcomes.
    Hassan Z; Boulos F; Abbas J; El Charif MH; Assi H; Sbaity E
    Breast Cancer Res Treat; 2020 Jul; 182(2):317-323. PubMed ID: 32462260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological Characteristics and Survival Outcomes in Invasive Papillary Carcinoma of the Breast: A SEER Population-Based Study.
    Zheng YZ; Hu X; Shao ZM
    Sci Rep; 2016 Apr; 6():24037. PubMed ID: 27053333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive Papillary Carcinoma of the Breast: Clinicopathological Features and Hormone Receptor Profile.
    Hashmi AA; Munawar S; Rehman N; Ahmed O; Islam S; Asghar IA; Afzal A; Irfan M; Shamail F; Ali SJ
    Cureus; 2021 Feb; 13(2):e13480. PubMed ID: 33777568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic study of invasive micropapillary carcinoma of the breast.
    Tang SL; Yang JQ; Du ZG; Tan QW; Zhou YT; Zhang D; Lv Q
    Oncotarget; 2017 Jun; 8(26):42455-42465. PubMed ID: 28418916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis.
    Hao S; Zhao YY; Peng JJ; Ren F; Yang WT; Yu KD; Shao ZM
    Sci Rep; 2019 Jan; 9(1):286. PubMed ID: 30670771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
    Chen HL; Ding A
    Breast; 2015 Dec; 24(6):723-31. PubMed ID: 26392199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall survival is improved when DCIS accompanies invasive breast cancer.
    Kole AJ; Park HS; Johnson SB; Kelly JR; Moran MS; Patel AA
    Sci Rep; 2019 Jul; 9(1):9934. PubMed ID: 31289308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
    Mercogliano MF; Inurrigarro G; De Martino M; Venturutti L; Rivas MA; Cordo-Russo R; Proietti CJ; Fernández EA; Frahm I; Barchuk S; Allemand DH; Figurelli S; Deza EG; Ares S; Gercovich FG; Cortese E; Amasino M; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    BMC Cancer; 2017 Dec; 17(1):895. PubMed ID: 29281999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.